 |
EpiCept Corporation Confirms Engagement of SunTrust Robinson Humphrey to Include Evaluation of Potential Sale Transactions
Jan 24, 2012
|
12.7 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT)
today confirmed that its engagement of SunTrust Robinson Humphrey to
assist in exploring strategic alternatives to maximize the commercial
opportunity of AmiKet™ i...
|
|
EpiCept Corporation Receives Finalized FDA Guidance for AmiKet™ Phase III CIPN Program and Regulatory Strategy
Jan 23, 2012
|
15.0 KB |
|
| |
Clear Pathway for NDA Filing Identified; Fast Track Application
Encouraged
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT)
today announced that it received further encouraging guidance for th...
|
|
EpiCept Corporation Engages SunTrust Robinson Humphrey to Advise on Strategy to Maximize AmiKet™ Potential
Jan 9, 2012
|
13.6 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT)
today announced that it has engaged SunTrust Robinson Humphrey to assist
in exploring strategic alternatives to maximize the commercial
opportunity of AmiKet™, the...
|
|
EpiCept to Present at Two Upcoming Industry Conferences
Jan 5, 2012
|
12.7 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT)
today announced that Jack Talley, President and CEO, will be presenting
at two upcoming industry conferences.
The Biotech Showcase 2012 Confe...
|
|
EpiCept Corporation Appoints Alan W. Dunton, M.D. Non-Executive Chairman of the Board
Jan 5, 2012
|
13.5 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT)
today announced that Alan W. Dunton, M.D., has been appointed to the
Company's Board of Directors and named Non-Executive Chairman, effective
immediately. Dr. Dunton rep...
|
|
EpiCept Corporation Receives FDA Permission to Initiate AmiKet™ Phase III Clinical Development
Dec 23, 2011
|
12.8 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT)
today announced that at a meeting earlier this week with the U.S. Food
and Drug Administration (FDA), the Company was granted permission to
initiate immediately the ...
|
|
EpiCept Provides Update on Ceplene® Manufacturing at Ben Venue Laboratories
Dec 21, 2011
|
12.3 KB |
|
| |
Supplies Available for Patients in European Union
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT)
today provided an update on the impact of the quality assurance review
by the European Medicines ...
|
|
EpiCept to Present at the 22nd Annual Wall Street Institutional Investor Conference
Nov 30, 2011
|
11.9 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT)
today announced that Jack Talley, President and Chief Executive Officer,
will be presenting at the 22nd Annual Wall Street
Institutional Investor Conference on Tuesday, ...
|
|
EpiCept to Present at the NYSSA Biotech and Specialty Pharma Conference
Nov 22, 2011
|
12.0 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT)
today announced that Jack Talley, President and Chief Executive Officer,
will be presenting at the New York Society of Security Analysts' (NYSSA)
15th Annual Biotech and...
|
|
EpiCept Corporation Reports Third Quarter 2011 Operating and Financial Results
Nov 8, 2011
|
37.3 KB |
|
| |
Conference Call Begins at 9:00 A.M. Eastern Time
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT)
today announced operating and financial results for the three and nine
months ended September 30, ...
|
|
EpiCept to Report Third Quarter 2011 Operating and Financial Results on November 8th, 2011
Nov 2, 2011
|
12.2 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT)
announced today that it will host a conference call to discuss third
quarter 2011 operating and financial results on Tuesday, November 8,
2011 at 9:00 a.m. Eastern time....
|
|
EpiCept Common Stock to Begin Trading on OTCQX®, The Highest Tier of the OTC Market, on September 19, 2011
Sep 15, 2011
|
14.0 KB |
|
| |
Withdraws from Nasdaq; Avoids Reverse Split
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and Nasdaq: EPCT)
today announced that its common stock will begin trading on the OTCQX®
U.S. trading platform ...
|
|
EpiCept Corporation Provides U.S. Regulatory Update for Ceplene® Clinical Development
Sep 12, 2011
|
13.1 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and Nasdaq: EPCT)
today announced that at a recent meeting with the U.S. Food and Drug
Administration (FDA) the Company was provided more definitive guidance
regarding the clinical devel...
|
|
EpiCept Common Stock Approved for Primary Listing on OMX Stockholm Exchange
Sep 7, 2011
|
11.8 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and Nasdaq: EPCT)
today announced that Nasdaq OMX Stockholm AB has approved the Company's
request for a primary listing of its common stock on the Nasdaq OMX
Stockholm Exchange. The Comp...
|
|
EpiCept to Present at Two Upcoming Industry Conferences
Aug 31, 2011
|
12.6 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT)
today announced that Jack Talley, President and CEO, will be presenting
at two upcoming industry conferences.
The Stifel Nicolaus 2011 Healt...
|
|
EpiCept Corporation Reports Second Quarter 2011 Financial Results and Provides Business Update
Aug 15, 2011
|
31.3 KB |
|
| |
Conference Call Begins at 9:00 A.M. Eastern Time Today
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT)
today announced operating and financial results for the three and six
months ended June 30,...
|
|
EpiCept Corporation Announces Publication in Journal Blood of a New Meta-Analysis Examining Lack of Efficacy of Interleukin-2 as Monotherapy in AML Remission Maintenance
Jul 18, 2011
|
14.1 KB |
|
| |
Meta-Analysis of Six International Randomized AML Trials Clearly
Shows No Benefit for Interleukin-2 without Ceplene®
Combination Therapy
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT)
...
|
|
EpiCept Receives Initial FDA Comments on Application for Ceplene® Special Protocol Assessment
Jun 27, 2011
|
12.5 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT)
today announced that it has received initial written responses from the
U.S. Food and Drug Administration (FDA) regarding the Company's
application for a Special Protoc...
|
|
EpiCept Announces Webcast of Annual Shareholder Meeting
Jun 22, 2011
|
12.2 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT)
today announced that the continuation of its annual shareholder meeting
will be accessible to investors via webcast. The annual meeting will be
held on Monday, June 27,...
|
|
EpiCept Seeks Primary Listing Status on OMX Stockholm Exchange
Jun 22, 2011
|
12.1 KB |
|
| |
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT)
today announced that it has applied for a primary listing on the Nasdaq
OMX Stockholm Exchange in recognition of the Company's large Swedish
shareholding base and the h...
|
|
|
